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Light-activatable immunoconjugates have recently shown promise for photoimmunotherapy and fluorescence-
guided resection in patients suffering from incurable malignancies in early clinical trials. While possessing a 
number of unique advantages, photoimmunotherapy and fluorescence imaging for oncological diseases can be 
hampered by therapeutic inefficiency resulting from inadequate photosensitizer delivery. The study suggests 
that successful coupling of antibody-photosensitizer photoimmunoconjugates onto polymeric nanoparticles 
complements the promising attributes of simple photoimmunoconjugates in two significant ways: Not only does 
it improve photosensitizer delivery to tumor, but also offers a forward-looking opportunity to deliver significant 
and diverse second agents, which can be an imaging agent or a different therapeutic agent, to further enhance 
the theranostic benefits of photoimmunoconjugates. This approach, based on nanoparticle engineering, 
achieves effective photoimmunoconjugate delivery and enhances the anti-tumor efficacy in two EGFR-
overexpressing cancer cell lines in vitro and in a xenograft tumor mouse model. Furthermore, the selectivity, 
photochemical and photophysical characteristics (e.g. absorbance, fluorescence quenching, and singlet oxygen 
yield) of the photoimmunoconjugated nanoplatform were thoroughly investigated. This next generation 
photoimmunoconjugate–nanoparticle delivery approach offers a unique opportunity to monitor disease, destroy 
cancer cells and co-deliver a follow-up treatment more efficiently, and thus merits further investigations in 
preclinical and clinical settings. 
 
